1. Home
  2. MXL vs IBRX Comparison

MXL vs IBRX Comparison

Compare MXL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$70.20

Market Cap

8.5B

Sector

Technology

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.32

Market Cap

7.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXL
IBRX
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
7.5B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
MXL
IBRX
Price
$70.20
$7.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
$41.67
$12.57
AVG Volume (30 Days)
3.8M
9.5M
Earning Date
04-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
46.08
38.71
EPS
N/A
N/A
Revenue
$478,596,000.00
$113,288,000.00
Revenue This Year
$22.10
$88.59
Revenue Next Year
$10.70
$131.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
668.31
52 Week Low
$12.77
$1.95
52 Week High
$128.30
$12.43

Technical Indicators

Market Signals
Indicator
MXL
IBRX
Relative Strength Index (RSI) 42.06 45.44
Support Level $15.70 $6.68
Resistance Level $100.90 $8.46
Average True Range (ATR) 7.32 0.41
MACD -0.60 -0.02
Stochastic Oscillator 22.17 38.26

Price Performance

Historical Comparison
MXL
IBRX

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: